SYSTEMATIC REVIEW/META-ANALYSIS

Title

Firstname Middleinitial. Lastname, Firstname Middleinitial. Lastname, and Firstname Middleinitial. Lastname

ABSTRACT BACKGROUND: State the background information/rationale for the investigation. Maximum abstract length is 350 words. No references should be cited. PURPOSE: State your specific purpose. DATA SOURCES: Indicate where you've gathered your data. STUDY SELECTION: Describe criteria for including/excluding studies. DATA ANALYSIS: Summarize methods used to examine the data. DATA SYNTHESIS: Explain how findings were combined or compared. LIMITATIONS: List potential weaknesses or biases in the study. CONCLUSIONS: Highlight the main findings in relation to the study's purpose.
ABBREVIATIONS: ABC ＝ definition; XYZ ＝ definition. Received month day, year; accepted after revision month day, year. From the Department of X (Firstinitial.Middleinitial.Lastinitial., Firstinitial.Middleinitial.Lastinitial.), Centre for Y (Firstinitial.Middleinitial.Lastinitial.), and Department of Z (Firstinitial.Middleinitial.Lastinitial.), Institution Name, City, State, Country; Department of L (Firstinitial.Middleinitial.Lastinitial., Firstinitial.Middleinitial.Lastinitial.), Institution Name, City, State, Country. Disclosure of potential conflicts of interest should be included here. Please address correspondence to Firstname Middleinitial. Lastname, degrees, Department of X, Institution, Street address, City, State Zip Code, Country; e-mail.

INTRODUCTION

Introduction should be placed here. Please write a brief introduction to the paper that outlines the Background/Purpose in further detail.

MATERIALS AND METHODS

Subsection Header

This section may be divided into subsections if it facilitates reading the paper. The research design, patients/subjects, material used, means of confirming diagnoses, and statistical methods should be included. Do not include manufacturer's names unless the specific product is important to the procedures performed. When appropriate, indicate that approval was obtained from the institution's review board. Indicate that informed consent has been obtained from patients who participated in clinical investigations.

In animal experimentation, acknowledge that National Institutes of Health or equivalent guidelines were followed. If there is a sponsoring company, include at the end of this section what input that company had in the formulation of the paper.

FIG 1. Description. You should incorporate your figures in the revision template, but you should also upload them as separate, high-resolution files, as per the instructions in the comment. Detailed figure and legend requirements can also be found in the submission guidelines.

RESULTS

This section may be divided into subsections if it facilitates reading the paper. Do not mix results and discussion into this section. Present results in a clear, orderly fashion, and include statistical findings to substantiate the results.

All results based on methods must be included. If tables and graphic material will ease the understanding of the results, include them. However, when the results can be summarized easily in a narrative form, do not use tables. Cite figures to illustrate findings.

DISCUSSION

Start with limited, pertinent background information and then discuss the results of the investigation in light of what has been published in the past, the limitations of your study, the implications for patient care, and potential directions for future research. The promise of further studies by the authors should be eliminated unless these are certain to be undertaken and should not be used as an excuse for study limitations.

Authors should also avoid statements indicating theirs is the first study of its kind unless this can be documented and the work is truly unique. Where appropriate, cite figures and graphs.

Table 1: XYZ.

Column A
Total A	X
Total B	YZD
C	A (XY.Z%)
D	B (CD.E%)
Age (yr)
Z	54
D	22–82
Total Z	243
Median	5
Range	234-235
ABCDE
A	B
B	A
C	C
D	D
E	E
Z	E

CONCLUSIONS

In a separate section, summarize the major findings of the study and their clinical usefulness (if applicable). This paragraph should address the hypothesis or purpose stated earlier in the paper.

ACKNOWLEDGMENTS

Acknowledgments have to be in a separate section but it does not have to be a freestanding page. Obtaining permission to include a name in this section from the acknowledged individual is advised.

REFERENCES

Callen AL, Chow DS, Chen YA, et al. Predictive value of noncontrast head CT with negative findings in the emergency department setting. AJNR Am J Neuroradiol 2020;41:213-18. DOI: https://doi.org/10.3174/ajnr.A6408

Lanzino G, Crobeddu E, Cloft HJ, et al. Efficacy and safety of flow diversion for paraclinoid aneurysms: a matched pair analysis compared with standard endovascular approaches. AJNR Am J Neuroradiol 2012 Jul 12.

Friedman ER, Tandon N. Beyond mesial temporal sclerosis: optimizing MRI evaluation in focal epilepsy. Neurographics http://dx.doi.org/10.3174/ng.2130053

Grossman RI, Yousem DM. Neuroradiology: The Requisites. Mosby; 1994:114-16

Hudgins PA, Jacobs IN, Castillo M. MR of the neck. In: Som PM, Curtin HD, eds. Head and Neck Imaging 3rd ed. St Louis: Mosby; 1996:545-611

Molyneaux AJ, Fox A, Sneade M, et al. Cerecyte coil trial: angiographic and clinical outcomes of endovascular coiling in patients with ruptured and unruptured intracranial aneurysms treated with Cerecyte coils compared with bare platinum coils—finals results of a prospective randomized trial. In: Proceedings of the American Society of Neuroradiology 50th Annual Meeting & the Foundation of the ASNR Symposium, New York, New York. April 21–26, 2012

The human brain: renew—exercise. http://www.fi.edu/learn/brain/exercise.html Accessed May 30, 2012

SUPPLEMENTAL FILES